Results

Total Results: 1,939 records

Showing results for "event".

421. Value Dossier (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/topic-nomination-fecal-incontinence-supporting.pdf
     June 19, 2020 - A third patient experienced a serious treatment-related adverse event of rectal abscess during the … These events resolved following treatment without sequalae within 35 days of event onset.9 • The … A third patient experienced a serious treatment-related adverse event of rectal abscess during the … These events resolved following treatment without sequalae within 35 days of event onset.9 Another … In the open phase, a third patient experienced a serious treatment-related adverse event of rectal

422. Acute Treatment for Episodic Migraine: Surveillance Report 2 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/episodic-migraine-surveillance-report-2.pdf
     June 01, 2022 - I² =N/A Patients with adverse events RR: 1.10; 95% CI: 0.95 to 1.28; I² =N/A Serious adverse event … I² =N/A Patients with adverse events RR: 2.67; 95% CI: 2.07 to 3.44; I² =N/A Serious adverse event … I² =N/A Patients with adverse events RR: 2.42; 95% CI: 1.87 to 3.15; I² =N/A Serious adverse event

423. Nonpharmacological Versus Pharmacological Treatment for Patients With Major Depressive Disorder: Current State of the Evidence (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/major-depressive-disorder_clinician.pdf
     September 01, 2016 - Nonpharmacological Versus Pharmacological Treatment for Patients With Major Depressive Disorder: Current State of the Evidence Nonpharmacological Versus Pharmacological Treatment for Patients With Major Depressive Disorder: Current State of the Evidence Focus of This Summary This is a summary of a systematic revie…

424. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cancer-radiation_executive.pdf
     November 01, 2009 - Layout 1 Background Radiotherapy with charged particles can potentially deliver maximal doses while minimizing irradiation of surrounding tissues. It may be more effective or less harmful than other forms of radiotherapy for some cancers. Currently, seven centers in the United States have facilities for particle (pr…

425. Executive Summary: Radiation Therapy for Metastatic Bone Disease: Effectiveness and Harms (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-265-radiation-bone-disease-summary.pdf
     August 01, 2023 - Executive Summary: Radiation Therapy for Metastatic Bone Disease: Effectiveness and Harms Comparative Effectiveness Review Number 265 Radiation Therapy for Metastatic Bone Disease: Effectiveness and Harms Executive Summary Main Points Background and Purpose Bone metastases are common in advan…

426. Evidence Report on the (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/weight-loss-surgery_research-protocol.pdf
     December 14, 2010 - In the event that data are lacking, an assessment should be made of what are the key variables influencing … Summary of Protocol Amendments In the event of protocol amendments, the date of each amendment will

427. High-Cholestorol-Medicines-Update Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/high-cholestorol-medicines-update_executive.pdf
     February 01, 2014 - NCEP ATP III = National Cholesterol Education Program Adult Treatment Panel IIL; SAE = serious adverse event

428. Juvenile-Arthritis-Dmards Surveillance (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/juvenile-arthritis-dmards_surveillance.pdf
     March 14, 2013 - Recently published studies of adverse event reporting databases provide indirect evidence that suggests … Recently published studies of adverse event reporting databases provide indirect evidence that suggests

429. Juvenile-Arthritis-Dmards Surveillance (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/juvenile-arthritis-dmards_surveillance.pdf
     March 14, 2013 - Recently published studies of adverse event reporting databases provide indirect evidence that suggests … Recently published studies of adverse event reporting databases provide indirect evidence that suggests

430. Surveillance-Report-1-Treatments-For-Acute-Pain (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/surveillance-report-1-treatments-for-acute-pain.pdf
     January 01, 2022 - hours versus acetaminophen, though opioids were associated with increased likelihood of any adverse event … Opioids were associated with increased likelihood of any adverse event (34% vs. 9%, RR 3.62, 95% CI … Topical ibuprofen was associated with decreased likelihood of any adverse event, though the estimate … Opioids were associated with increased likelihood of any adverse event (11 trials, pooled RR 1.72, 95% … It also found that NSAIDS might be associated with slightly decreased risk of any adverse event versus

431. Vitamin D and Calcium: A Systematic Review of Health Outcomes | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/vitamin-d-calcium/research-protocol
     June 10, 2013 - For upper limit (adverse event [AE]) outcomes, we will include any adverse effects of high intake in … Summary of Protocol Amendments In the event of protocol amendments, the date of each amendment will

432. Tympanostomy Tubes in Children With Otitis Media (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/tympanostomy-tubes-executive-170523.pdf
     May 01, 2017 - The number of publications reporting each event, and the median (with 25th and 75th percentiles) percent … Median percentage of patients and ears with adverse events associated with TT placement Adverse Event … number of patients (ears) < 5; TT=Tympanosotomy Tubes See Appendix G of the full report for adverse event … the RCTs are systematically higher in both control and intervention arms in the RCTs compared with event … Several adverse event categories have very wide interquartile ranges (e.g. otorrhea, premature extrusion

433. Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/antiplatelet-treatment/research-protocol
     November 22, 2011 - of CYP2C19 alleles among different ethnic groups), comorbid conditions (that may affect the baseline event … platelet reactivity is an intermediate phenotype between exposure to a drug and occurrence of a clinical event … (e.g., an arterial thrombotic event), we refer to tests of platelet reactivity as “phenotypic tests” … Summary of Protocol Amendments In the event of protocol amendments, the date of each amendment will

434. Disposition of Comments for Technical Brief 24 Resident Safety Practices (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/nursing-home-safety_disposition-comments.pdf
     May 27, 2016 - Avoidable decline in ADLS may be viewed as harm not a potentially contributing factor to an adverse event … Peer reviewer #5 Background Why is dementia not a contributing event? … issues as defined in Patient Safety Organization Privacy Protection Center (PSOPPC) Common Formats for Event … We focused on the 4 safety events as currently identified in the PSOPPC Common Formats for Event Reporting … We focused on the 4 safety events as currently identified in the PSOPPC Common Formats for Event Reporting

435. Future Research Needs for First- and Second-Generation Antipsychotics for Children and Young Adults (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/antipsychotics-children-future_research.pdf
     February 01, 2012 - For SGAs, adverse event profiles of various SGAs showed that risperidone was favored over olanzapine … comparisons between and within classes of 1st and 2nd generation antipsychotics for any shorter term adverse event … Cardiomyopathies • Cardiac arrhythmias • Agranulocytosis • Extrapyramidal effects General adverse event … evidence to favor placebo over several 2nd generation antipsychotics with respect to several adverse event … for comparisons between and within classes of 1st and 2nd generation antipsychotics for any adverse event

436. Evidence Report on the (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/measuring-blood-pressure_research-protocol.pdf
     April 11, 2011 - Summary of Protocol Amendments In the event of protocol amendments, the date of each amendment will

437. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/procalcitonin_research-protocol.pdf
     September 08, 2011 - Evidence-based Practice Center Systematic Review Protocol Source: www.effectivehealthcare.ahrq.gov Published Online: September 8, 2011 Evidence-based Practice Center Systematic Review Protocol Project Title: Procalcitonin for Diagnosis and Management of Sepsis Amendment Date(s) if applicable: (Amendm…

438. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/sleep-apnea_research-protocol.pdf
     March 15, 2010 - Depression event (diagnosis, recurrence, etc.) 9. Intermediate or Surrogate outcomes a. … Summary of Protocol Amendments In the event of protocol amendments, the date of each amendment will

439. Acute Treatment for Episodic Migraine: Surveillance Report 2 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/product/pdf/episodic-migraine-surveillance-report-2.pdf
     June 01, 2022 - I² =N/A Patients with adverse events RR: 1.10; 95% CI: 0.95 to 1.28; I² =N/A Serious adverse event … I² =N/A Patients with adverse events RR: 2.67; 95% CI: 2.07 to 3.44; I² =N/A Serious adverse event … I² =N/A Patients with adverse events RR: 2.42; 95% CI: 1.87 to 3.15; I² =N/A Serious adverse event

440. Systematic Review on Nonopioid Pharmacologic Treatments for Chronic Pain: Surveillance Report 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/surveillance-report-1-nonopioid-pharm-chronic-pain.pdf
     April 01, 2022 - No change in conclusions Abbreviations: AE=adverse event; CBD=cannabidiol; CR=controlled release; … with increased risk of withdrawal versus placebo (2.1% vs. 0%, p>0.05).6 The most common adverse event